Abstract: A composition effective for treating circulation disorders comprises a mixture of ##STR1## wherein the variables can have varied meetings. I are inotropic and II are vasodilating but, whereas the ingredients in the combination would be expected to be antagonistic, they are reinforcing.

Abstract: Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is H, CN, NO.sub.2 or --COOR.sup.7,R.sup.7 is H, alkyl or various other radicals,R.sup.2 and R.sup.4 each independently is alkyl or other radicals,R.sup.3 is H or optionally substituted alkyl,R.sup.5 completes a keto or ester group, andR.sup.6 is a direct bond or --CF.sub.2 -- or --CHF--,and physiologically acceptable salts thereof.

Abstract: Cardioactive novel dihydropyridine ethers of the formula ##STR1## in which R.sup.1 -stands for cyano, nitro or for a -COOR.sup.5 group,whereinR.sup.5 -denotes straight-chain, branched or cyclic alkyl having up to 6 carbon atoms, which can be interrupted by an oxygen in the chain and which can be monosubstituted or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxyl, phenyl, phenoxy or by a group of the formula ##STR2## R.sup.2 -stands for aryl having 6 to 12 carbon atoms, which can be monosubstituted, disubstituted or trisubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, alkyl having up to 4 carbon atoms or alkoxy having up to 4 carbon atoms,R.sup.3 -stands for aryl having 6 to 12 carbon atoms, or stands for straight-chain, branched or cyclic alkyl having up to 6 carbon atoms andR.sup.

Abstract: A solid medicament formulation which can be administered orally, comprising 1 to 40 mg of a dihydropyridine of the formula ##STR1## in which R.sup.1 and R.sup.3 are always different from one another and represent alkyl which has 1 to 12 carbon atoms and which is optionally substituted once or several times by fluorine or chlorine or which is optionally interrupted by an oxygen atom in the chain, andA represents the radical ##STR2## R.sup.2 representing one or two substituents from the group consisting of nitro, chlorine and trifluoromethyl, or represents and 0.1 to 100 mg of a cardioactive nitrate. The composition is cardio-active and the patient's tendency toward nitrate tolerance is reduced.

Abstract: For the treatment of circulation disorders, the novel 5-nitro-1,4-dihydropyridines of the formula ##STR1## in which R represents C.sub.6 -C.sub.14 -aryl which can be mono- to pentasubstituted by identical or different substituents from the series comprising halogen, nitro, cyano, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio and benzyl, benzyloxy or benzylthio optionally substituted by nitro, cyano, trifluoromethyl, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy, orrepresents a heterocycle from the series pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl optionally mono- to tetrasubstituted by halogen, phenyl or C.sub.1 -C.sub.4 -alkyl orrepresents straight-chain, branched or cyclic alkyl with up to 14 carbon atoms,and their physiologically acceptable salts.

Abstract: Circulatory system-active novel dihydropyrimidines of the formula ##STR1## in which R.sup.1 and R.sup.6 are diverse organic radicals, and pharmacologically acceptable addition salts thereof.

Abstract: 4 Aminoaryldihydropyridines of the formula ##STR1## in which R.sup.1 is hydrogen or an organic radical, preferably methyl or ethyl,R.sup.2 is hydrogen, C.sub.1 -C.sub.5 -alkyl, --CN, --NH.sub.2, --CH.sub.2 or --CH.sub.2 OH, preferably methyl,R.sup.3 is hydrogen or alkyl, preferably hydrogen,Y is --CO-- or --SO.sub.2 --, andR.sup.4 is an organic radical, orY--R.sup.4 is hydrogen,and physiologically acceptable salts thereof, are circulation-active and effective for improving myocardial contractility, for raising blood pressure, for lowering blood sugar, for reducing mucosal swelling and for controlling the salt and fluid balance.

Abstract: An antihypertensive and antianginal combination comprising (A) 0.1 to 10 parts by weight of an asymmetrical dihydropyridine of the formula ##STR1## in which R.sup.1 and R.sup.5 each independently is methyl, hydroxymethyl or cyano,R.sup.2 and R.sup.4 are always different from one another and each independently is alkyl with 1 to 10 carbon atoms optionally substituted by alkoxy with 1 to 4 carbon atoms, fluorine, chlorine or N-methyl-benzylamino,R.sup.3 is nitro, chlorine, trifluoromethyl, or .dbd.N--O--N.dbd., and n is 1 or 2,and (B) about 10 to 200 parts by weight of a .beta.-blocker preferably without a local anesthetic action.

Abstract: 5-Aryl-1,4-dihydropyridines of the formula ##STR1## in which Rrepresents cycloalkyl,heteroaryl oraryl which is optionally substituted by at least one substituent independently selected from the group consisting of halogen, nitro, hydroxyl, amino, carboxyl, alkoxycarbonyl, cyano, acyl, acyloxy, acylthio, by alkyl, alkyloxy, alkylthio or alkylsulphonyl, each of which is optionally substituted by one or more halogens, by aryl which is optionally substituted by alkyl, alkoxy, halogen or nitro, or optionally by the group --Z--CH.sub.2 --R.sup.4,whereZ represents oxygen or sulphur, andR.sup.4represents cycloalkyl,heteroaryl oraryl which is optionally substituted by halogen, cyano, nitro, hydroxyl, carboxyl, alkoxycarbonyl or by alkyl or alkoxy, each of which is optionally substituted by one or more halogens,R.sup.1 and R.sup.2are identical or different andrepresent straight-chain or branched alkyl which is optionally substituted by aryl, carboxyl, alkoxycarbonyl or by hydroxyl,R.sup.

Abstract: Novel cardioactive compounds of the formula ##STR1## in which R.sup.1 is alkyl, aryl or heterocyclic, preferably substituted phenyl,R.sup.2 is alkyl, preferably methyl,R.sup.3 is hydrogen, halogen, acyloxy or alkyl, preferably hydrogen, andR.sup.4 is phenyl, carbalkoxy or together with R.sup.3 forms a ring, preferably carbalkoxy,are produced by reducing the corresponding nitro compounds.

Abstract: Novel circulation active dihydropyridines of the formula ##STR1## in which X is CO, SO.sub.2 or CONH,R.sup.4 is H, OH, alkyl, halogen, acyloxy, alkoxyalkoxy, aralkyloxy, or together with R.sup.5 forms a heterocyclic ring, andthe other radicals are conventional in the dihydropyridine art,and pharmaceutically acceptable salts thereof.

Abstract: Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is optionally substituted aryl or heterocyclic,R.sup.2 is H, NO.sub.2, CN, C.sub.1 -C.sub.8 -alkylsulphonyl, aryl or carboalkoxy,R.sup.3 is alkyl or aryl,R.sup.4 is H or alkyl,X is C.dbd.O or a direct bond, andn is a number from 1 to 20,or physiologically acceptable salts thereof. A synthesis using morpholines or thiomorpholines is also disclosed.

Abstract: Pure enantiomers of 5-nitrodihydropyridine of the formula ##STR1## are mixed, wherein one of the enantiomers has a high vasodilative action and a low negative inotropic activity on heart muscle, the other enantiomer has a low vasoconstrictive action and a high positive inotropic activity on heart muscle, the mixture being high in vasodilative activity and in positive inotropic activity on heart muscle.

Abstract: 1-Oxo-1,3,4,7-tetrahydrobenzofuranes of the formula ##STR1## in which X is O or S,R is optionally substituted phenyl or heteroaryl,R.sup.1 is OH, monoalkylamino or dialkylamino, andR.sup.2 is an acyl or esterified carboxy radical,or pharmacologically acceptable salts thereof, which are active in circulation, e.g. they increase myocardial contractility, increase the flow of Ca.sup.2+ into the cell, increase blood pressure, reduce blood sugar, reduce swelling of mucous membranes and affect the salt and/or fluid balance.

Abstract: 1,4-Dihydropyridine-3-carboxylic acid piperazides of the formula ##STR1## in which R.sup.1 is CN or alkyl, preferably methyl,R.sup.2 is H, CN, NO.sub.2 or preferably carboxyalkyl,R.sup.3 is aryl or heterocyclic, andR.sup.4 is alkyl, cycloalkyl, aryl or an acyl radical,and physiologically acceptable salts thereof, are circulation active. Novel intermediates are also provided.

Abstract: A solid medicament formulation which can be administered orally comprising 5 to 30 mg of nifedipine and 10 to 40 mg of isosorbide 5-mononitrate. Oral administration of such cardioactive formulation reduces the time tolerance to the isosorbide 5-mononitrate alone.

Abstract: Novel compounds of the formula ##STR1## in which R.sup.2 is hydrogen or a substituent, andR.sup.1 is optionally substituted alkyl or alkenyl,exhibit positive inotropic activity on the cardiac muscle, intensifying the contraction power.

Abstract: 1,4-Dihyropyridinecarboxamides of the formula ##STR1## and salts thereof, are effective for treating cardiac insufficiency, thromboses, thromboembolisms and ischaemias, for influencing the blood-sugar level and the circulation and as coronary therapeutic agents and anti-arrhythmic agents.

Abstract: 1-Oxo-1,3,4,7-tetrahydrobenzofuranes of the formula ##STR1## in which X is O or S,R is optionally substituted phenyl or heteroaryl,R.sup.1 is OH, monoalkylamino or dialkylamino, andR.sup.2 is an acyl or esterified carboxy radical, or pharmacologically acceptable salts thereof, which are active in circulation, e.g. they increase myocardial contractility, increase the flow of Ca.sup.2+ into the cell, increase blood pressure, reduce blood sugar, reduce swelling of mucous membranes and affect the salt and/or fluid balance.

Abstract: Hydroxytetrahydropyridinelactones of the formula ##STR1## in which R represents a phenyl, naphthyl, thienyl, furyl, pyrryl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, quinolyl, isoquinolyl, indolyl, benzimidazolyl, quinazolyl, quinoxalyl, thionaphthenyl, isothionaphthenyl, chromonyl, thiochromonyl, chromenyl, thiochromenyl, benzoxadiazolyl or benzthiadiazolyl radical, and the stated radicals may carry 1 to 3 identical or different substituents from the group comprising C.sub.1 -C.sub.20 -alkyl, C.sub.2 -C.sub.20 -alkenyl, C.sub.2 -C.sub.20 -alkinyl, C.sub.1 -C.sub.20 -alkoxy, fluorine, chlorine, bromine, iodine, trifluoromethyl, monofluoro-C.sub.1 -C.sub.10 -alkoxy, polyfluoro-C.sub.1 -C.sub.10 -alkoxy, hydroxyl, amino, mono-C.sub.1 -C.sub.10 -alkylamino, di-C.sub.1 -C.sub.10 -alkylamino, nitro, cyano, azido, carboxyl, carb-C.sub.1 -C.sub.10 -alkoxy, carboxamido, sulphonamido, SO.sub.